In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Agios Pharmaceuticals Inc (NASDAQ: AGIO) closed at $24.46 down -1.09% from its previous closing price of $24.73. In other words, the price has decreased by -$1.09 from its previous closing price. On the day, 3.74 million shares were traded. AGIO stock price reached its highest trading level at $25.305 during the session, while it also had its lowest trading level at $24.25.
Ratios:
For a deeper understanding of Agios Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.39 and its Current Ratio is at 13.82. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 20, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $34. RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 19, 2025, while the target price for the stock was maintained at $28.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 12 ’25 when Scadden David sold 200 shares for $43.84 per share. The transaction valued at 8,768 led to the insider holds 17,603 shares of the business.
Gheuens Sarah sold 2,454 shares of AGIO for $107,436 on Nov 11 ’25. The Chief Medical Officer now owns 61,727 shares after completing the transaction at $43.78 per share. On Nov 11 ’25, another insider, SARAH GHEUENS, who serves as the Officer of the company, bought 2,454 shares for $43.78 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 1426355840 and an Enterprise Value of 518010848. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.85 while its Price-to-Book (P/B) ratio in mrq is 1.11. Its current Enterprise Value per Revenue stands at 11.565 whereas that against EBITDA is -1.101.
Stock Price History:
The Beta on a monthly basis for AGIO is 0.91, which has changed by -0.30806226 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, AGIO has reached a high of $46.00, while it has fallen to a 52-week low of $22.24. The 50-Day Moving Average of the stock is -30.89%, while the 200-Day Moving Average is calculated to be -28.86%.
Shares Statistics:
For the past three months, AGIO has traded an average of 1.27M shares per day and 1502570 over the past ten days. A total of 58.28M shares are outstanding, with a floating share count of 54.95M. Insiders hold about 5.77% of the company’s shares, while institutions hold 101.98% stake in the company. Shares short for AGIO as of 1764288000 were 5466677 with a Short Ratio of 4.31, compared to 1761868800 on 4601630. Therefore, it implies a Short% of Shares Outstanding of 5466677 and a Short% of Float of 9.4399996.
Earnings Estimates
The firm’s stock currently is rated by 8.0 analysts. The consensus estimate for the next quarter is -$1.88, with high estimates of -$1.7 and low estimates of -$2.04.
Analysts are recommending an EPS of between -$5.58 and -$7.36 for the fiscal current year, implying an average EPS of -$7.01. EPS for the following year is -$6.57, with 10.0 analysts recommending between -$4.82 and -$8.37.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $12.04M this quarter.It ranges from a high estimate of $13.4M to a low estimate of $9M. As of. The current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $10.73MFor the next quarter, 10 analysts are estimating revenue of $16.04M. There is a high estimate of $18.07M for the next quarter, whereas the lowest estimate is $14.37M.
A total of 10 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $47.5M, while the lowest revenue estimate was $43.34M, resulting in an average revenue estimate of $46.1M. In the same quarter a year ago, actual revenue was $36.5MBased on 10 analysts’ estimates, the company’s revenue will be $108.57M in the next fiscal year. The high estimate is $191.3M and the low estimate is $67.25M.
